Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Focused specifically on examining gene therapy immunogenicity, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune ...

These properties, together with a favorable toxicity profile and minimal immunogenicity, indicate that AAV is likely to be a suitable vector for gene therapy applications which require sustained ...

They can infect both dividing and non-dividing cells and provide long-term gene expression. AAV vectors have a low immunogenicity profile, making them attractive for gene therapy applications.

INS1201 represents the first application of Insmed’s targeted adeno-associated virus (AAV) delivery platform ... which may overcome the immunogenicity barriers associated with existing viral ...

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research ...